Compare Alcon AG (ALC) vs Newmont Corporation (NEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Newmont Corporation — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Newmont Corporation trades at $93.02 (market cap $101.48B). The key difference: Newmont Corporation is far larger — about 3.1× Alcon AG's market cap, and Newmont Corporation pays the higher dividend (1.09%). Which is the better fit depends on your goals.
| ALC | NEM | |
|---|---|---|
Market Cap | $32.69B | $101.48B |
Sector | Health | Basic Materials |
52-Week High | $92.22 | $131.95 |
52-Week Low | $62.02 | $57.35 |
Enterprise Value | $36.28B | $98.23B |
Dividend Yield | 0.54% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Newmont Corporation (NEM) trades at $95.06, down 2.04% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $2.90 versus $2.07 expected, revenue growth to $22.67 billion in 2025, and robust cash flow of $10.33 billion from operations. Analyst consensus is bullish with a $144.00 price target and 75% buy ratings, though recent gold price volatility has pressured shares.
The outlook remains positive due to low valuation multiples (P/E 12.74, EV/EBITDA 6.27) and record free cash flow, but risks include gold market fluctuations and execution of expansion projects. The stock presents a value opportunity for long-term investors, supported by a strong balance sheet and dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
